Your browser doesn't support javascript.
loading
Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.
Varey, Alexander H R; Li, Isabel; El Sharouni, Mary-Ann; Simon, Julie; Dedeilia, Aikaterini; Ch'ng, Sydney; Saw, Robyn P M; Spillane, Andrew J; Shannon, Kerwin F; Pennington, Thomas E; Rtshiladze, Michael; Stretch, Jonathan R; Nieweg, Omgo E; van Akkooi, Alexander; Sullivan, Ryan J; Boland, Genevieve M; Gershenwald, Jeffrey E; van Diest, Paul J; Scolyer, Richard A; Long, Georgina V; Thompson, John F; Lo, Serigne N.
Afiliação
  • Varey AHR; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
  • Li I; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • El Sharouni MA; Department of Plastic & Reconstructive Surgery, Westmead Hospital, Sydney, NSW, Australia.
  • Simon J; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
  • Dedeilia A; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • Ch'ng S; Departments of Dermatology and Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Saw RPM; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Spillane AJ; Massachusetts General Hospital, Boston, MA.
  • Shannon KF; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
  • Pennington TE; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • Rtshiladze M; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
  • Stretch JR; Institute of Academic Surgery at RPA, Sydney Local Health District, Sydney, NSW, Australia.
  • Nieweg OE; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
  • van Akkooi A; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • Sullivan RJ; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
  • Boland GM; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
  • Gershenwald JE; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • van Diest PJ; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
  • Scolyer RA; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • Long GV; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
  • Thompson JF; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
  • Lo SN; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
J Clin Oncol ; 42(10): 1169-1180, 2024 Apr 01.
Article em En | MEDLINE | ID: mdl-38315961
ABSTRACT

PURPOSE:

Improvements in recurrence-free survival (RFS) were demonstrated in two recent randomized trials for patients with sentinel node (SN)-negative stage IIB or IIC melanoma receiving adjuvant systemic therapy (pembrolizumab/nivolumab). However, adverse events also occurred. Accurate individualized prognostic estimates of RFS and overall survival (OS) would allow patients to more accurately weigh the risks and benefits of adjuvant therapy. Since the current American Joint Committee on Cancer eighth edition (AJCC-8) melanoma staging system focuses on melanoma-specific survival, we developed a multivariable risk prediction calculator that provides estimates of 5- and 10-year RFS and OS for these patients.

METHODS:

Data were extracted from the Melanoma Institute Australia (MIA) database for patients diagnosed with stage II (clinical or pathological) melanoma (n = 3,220). Survival prediction models were developed using multivariable Cox regression analyses (MIA models) and externally validated twice using data sets from the United States and the Netherlands. Each model's performance was assessed using C-statistics and calibration plots and compared with Cox models on the basis of AJCC-8 staging (stage models).

RESULTS:

The 5-year and 10-year RFS C-statistics were 0.70 and 0.73 (MIA-model) versus 0.61 and 0.60 (stage-model), respectively. For OS, the 5-year and 10-year C-statistics were 0.71 and 0.75 (MIA-model) compared with 0.62 and 0.61 (stage-model), respectively. The MIA models were well calibrated and externally validated.

CONCLUSION:

The MIA models offer accurate and personalized estimates of both RFS and OS in patients with stage II melanoma even in the absence of pathological staging with SN biopsy. These models were robust on external validations and may be used in everyday practice both with (ideally) and without performing SN biopsy to identify high-risk patients for further management strategies. An online tool will be available at the MIA website (Risk Prediction Tools).
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: J Clin Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: J Clin Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália